Internal Medicine, Endocrinology, Diabetes, & Metabolism · Burleson, TX
NPI
1922028125
Since 2006
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
11803 South Fwy Ste 308
Burleson, TX, 76028
Phone (817) 568-1818
Groups this clinician bills Medicare through
Medicare paid, 2024
$123K
1,656 services
Medicare patients, 2024
442
Average age 74
Drug cost, 2024
$1.7M
5,125 prescriptions
Company payments, 2025
$363
From 9 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Imran A Patel was code 99213 (office e&m - established), 511 times for 218 patients. In total Imran A Patel billed 1,656 services in 11 codes, and Medicare paid $123K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2025-09-22.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99213 Office E&M - Established | Office | 511 | 218 | $58.47 | $30K |
| 99232 Hospital E&M - Subsequent | Facility | 433 | 34 | $60.91 | $26K |
| 99214 Office E&M - Established | Office | 409 | 156 | $90.14 | $37K |
| 99233 Hospital E&M - Subsequent | Facility | 176 | 28 | $91.80 | $16K |
| 99203 Office E&M - New | Office | 35 | 35 | $71.38 | $2,498 |
| 99215 Office E&M - Established | Office | 31 | 29 | $127.81 | $3,962 |
| 99223 Hospital E&M - Initial | Facility | 28 | 27 | $134.10 | $3,755 |
| 99204 Office E&M - New | Office | 21 | 21 | $121.64 | $2,554 |
By year: 2022 $156K for 2,105 services; 2023 $137K for 1,813 services; 2024 $123K for 1,656 services.
Medicare prescription drug claims, 2024
In 2024, the drug Imran A Patel prescribed most often to Medicare patients was Levothyroxine Sodium, with 1,051 prescriptions and refills. In total Imran A Patel wrote 5,125 Medicare prescriptions that cost $1.7M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Levothyroxine Sodium Generic | 1,051 | 2,435 | 246 | $9,038 |
| Glimepiride Generic | 568 | 1,498 | 162 | $5,979 |
| Metformin Hcl Generic | 398 | 1,075 | 114 | $3,357 |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | 292 | 648 | 97 | $86K |
| Glipizide Generic | 201 | 534 | 59 | $2,077 |
| Synthroid Levothyroxine Sodium | 193 | 423 | 45 | $14K |
| Tresiba Flextouch U-100 Insulin Degludec | 146 | 375 | 44 | $156K |
| Ozempic Semaglutide | 135 | 232 | 33 | $209K |
| Humalog Kwikpen U-100 Insulin Lispro | 131 | 303 | 50 | $66K |
| Toujeo Solostar Insulin Glargine,hum.Rec.Anlog | 118 | 230 | 33 | $121K |
| Jardiance Empagliflozin | 104 | 188 | 25 | $109K |
| Methimazole Generic | 103 | 212 | 26 | $764 |
| Januvia Sitagliptin Phosphate | 87 | 167 | 18 | $93K |
| Pioglitazone Hcl Generic | 81 | 173 | 23 | $927 |
| Novolog Flexpen Insulin Aspart | 81 | 184 | 37 | $34K |
Brand drugs: 2,431 claims; generic drugs: 2,364 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Imran A Patel $363 ($363 in general payments such as food, travel and fees) from 9 companies. The largest payer was Novo Nordisk Inc with $73.15.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.